We have reported previously that
PX-478 (S-2-amino-3-[4'-N,N,-bis(chloroethyl)amino]phenyl
propionic acid N-
oxide dihydrochloride) has potent antitumor activity against a variety of human
tumor xenografts associated with the levels of the
hypoxia-inducible factor-1alpha (HIF-1alpha) within the
tumor. We now report that
PX-478 inhibits HIF-1alpha
protein levels and transactivation in a variety of
cancer cell lines.
Hypoxia-induced
vascular endothelial growth factor formation was inhibited by
PX-478, whereas baseline levels of
vascular endothelial growth factor in normoxia were unaffected. Studies of the mechanism of
PX-478 action showed that HIF-1alpha inhibition occurs in both normoxia and
hypoxia and does not require pVHL or p53. In addition,
PX-478 decreases levels of HIF-1alpha
mRNA and inhibits translation as determined by 35S labeling experiments and reporter assays using the
5' untranslated region of HIF-1alpha. Moreover, to a lesser extent,
PX-478 also inhibits HIF-1alpha deubiquitination resulting in increased levels of polyubiquitinated HIF-1alpha. The inhibitory effect of
PX-478 on HIF-1alpha levels is primarily due to its inhibition of translation because HIF-1alpha translation continues in
hypoxia when translation of most
proteins is decreased. We conclude that
PX-478 inhibits HIF-1alpha at multiple levels that together or individually may contribute to its antitumor activity against HIF-1alpha-expressing
tumors.